Clinical

Dataset Information

0

Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.


ABSTRACT: Primary outcome(s): Response rate

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2626735 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| S-EPMC6113428 | biostudies-literature
| 2626734 | ecrin-mdr-crc
| S-EPMC4251687 | biostudies-literature
| S-EPMC10249423 | biostudies-literature
| S-EPMC4119993 | biostudies-literature
| S-EPMC6144158 | biostudies-literature
| S-EPMC6852115 | biostudies-literature
| S-EPMC7794191 | biostudies-literature
| 2625092 | ecrin-mdr-crc
| S-EPMC7659192 | biostudies-literature